Sanaby Health Acquisition Corp. I (SANB) announced it will dissolve and liquidate after failing to complete a business combination by the deadline of October 19, 2022. All outstanding shares of Class A common stock will be redeemed at approximately $10.22 per share. The company cited current market dynamics and economic uncertainty as reasons for the decision, emphasizing a commitment to returning capital to shareholders. The liquidation process will include the necessary actions to disburse funds from the trust account, with liquidations expected to be completed within ten business days following the announced date.
Sanaby Health Acquisition Corp. I (Nasdaq: SANBU) announced that starting November 9, 2021, holders of its 17,250,000 units can trade Class A common stock and warrants separately on The Nasdaq Global Market under the symbols SANB and SANBW, respectively. The units were offered in an initial public offering on October 14, 2021. Sanaby, a blank check company, aims to pursue mergers within the healthcare sector, specifically in digital health and innovative therapeutics, although no specific targets have been chosen.
Sanaby Health Acquisition Corp. I has successfully closed its initial public offering, raising $172,500,000 from the sale of 17,250,000 units priced at $10.00 each. The underwriters fully exercised their over-allotment option, contributing an additional 2,250,000 units. The units began trading on the Nasdaq under the ticker symbol “SANBU” on October 15, 2021. The Company aims to pursue business combinations, particularly in the healthcare sector, though no specific target has been identified as of yet.
Sanaby Health Acquisition Corp. I has announced the pricing of its initial public offering (IPO) of 15,000,000 units at $10.00 per unit. The units will start trading on The Nasdaq Global Market under the ticker symbol “SANBU” on October 15, 2021, with a closing date anticipated around October 19, 2021. Each unit includes one share of Class A common stock and a half warrant that is exercisable at $11.50 per share. The company aims to pursue business combinations in the healthcare sector, particularly focusing on digital health and innovative therapeutics.